Holocene Advisors LP Sells 93,712 Shares of Dyne Therapeutics, Inc. (NASDAQ:DYN)

Holocene Advisors LP trimmed its holdings in shares of Dyne Therapeutics, Inc. (NASDAQ:DYN - Free Report) by 4.5% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 1,982,640 shares of the company's stock after selling 93,712 shares during the quarter. Holocene Advisors LP owned about 1.95% of Dyne Therapeutics worth $71,216,000 at the end of the most recent quarter.

Several other hedge funds have also recently bought and sold shares of DYN. Nisa Investment Advisors LLC increased its holdings in shares of Dyne Therapeutics by 904.1% during the second quarter. Nisa Investment Advisors LLC now owns 743 shares of the company's stock worth $26,000 after buying an additional 669 shares in the last quarter. Quantbot Technologies LP acquired a new stake in shares of Dyne Therapeutics during the third quarter worth approximately $34,000. US Bancorp DE increased its holdings in shares of Dyne Therapeutics by 776.9% during the third quarter. US Bancorp DE now owns 1,368 shares of the company's stock worth $49,000 after buying an additional 1,212 shares in the last quarter. Values First Advisors Inc. acquired a new stake in shares of Dyne Therapeutics during the third quarter worth approximately $62,000. Finally, KBC Group NV increased its holdings in shares of Dyne Therapeutics by 53.4% in the third quarter. KBC Group NV now owns 2,157 shares of the company's stock valued at $77,000 after purchasing an additional 751 shares in the last quarter. 96.68% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Dyne Therapeutics

In related news, Director Dirk Kersten sold 79,411 shares of the stock in a transaction on Friday, September 20th. The shares were sold at an average price of $36.45, for a total transaction of $2,894,530.95. Following the transaction, the director now directly owns 234,127 shares of the company's stock, valued at $8,533,929.15. This represents a 25.33 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Jason P. Rhodes sold 782 shares of the stock in a transaction on Thursday, November 14th. The stock was sold at an average price of $33.10, for a total transaction of $25,884.20. Following the transaction, the director now directly owns 15,962 shares in the company, valued at approximately $528,342.20. This represents a 4.67 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 176,257 shares of company stock worth $6,193,718 over the last three months. 20.77% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

A number of equities analysts have issued reports on DYN shares. Piper Sandler reaffirmed an "overweight" rating and issued a $53.00 price objective on shares of Dyne Therapeutics in a research note on Monday, September 23rd. Stifel Nicolaus boosted their price objective on shares of Dyne Therapeutics from $41.00 to $66.00 and gave the company a "buy" rating in a research report on Friday, August 16th. Oppenheimer reiterated an "outperform" rating and issued a $55.00 price target on shares of Dyne Therapeutics in a research note on Tuesday, September 3rd. JPMorgan Chase & Co. lowered shares of Dyne Therapeutics from an "overweight" rating to a "neutral" rating and lowered their price target for the company from $43.00 to $35.00 in a research note on Thursday, October 24th. Finally, Chardan Capital reiterated a "buy" rating and issued a $50.00 price target on shares of Dyne Therapeutics in a research note on Wednesday, November 13th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating, nine have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $50.82.

Dyne Therapeutics Price Performance

DYN stock traded down $0.82 during trading on Tuesday, reaching $28.46. 382,391 shares of the company were exchanged, compared to its average volume of 1,467,751. The company has a 50-day moving average of $31.56 and a two-hundred day moving average of $35.48. The company has a market capitalization of $2.90 billion, a price-to-earnings ratio of -8.14 and a beta of 1.09. Dyne Therapeutics, Inc. has a twelve month low of $10.33 and a twelve month high of $47.45.

Dyne Therapeutics (NASDAQ:DYN - Get Free Report) last announced its quarterly earnings results on Tuesday, November 12th. The company reported ($0.96) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.71) by ($0.25). On average, analysts forecast that Dyne Therapeutics, Inc. will post -3.45 EPS for the current year.

Dyne Therapeutics Company Profile

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.